Increased spine bone density in patients with chronic hepatitis B switched to tenofovir alafenamide: A prospective, multinational study (vol 59, pg 239, 2024)

被引：0
|
作者：
Ogawa, Eiichi
Jun, Dae Won
Toyoda, Hidenori
Hsu, Yao-Chun
Yoon, Eileen L.
Ahn, Sang Bong
Yeh, Ming-Lun
Do, Son
Trinh, Huy N.
Takahashi, Hirokazu
Enomoto, Masaru
Kawada, Norifumi
Yasuda, Satoshi
Tseng, Cheng-Hao
Kawashima, Keigo
Lee, Han Ah
Inoue, Kaori
Haga, Hiroaki
Do, Ai-Thien
Maeda, Mayumi
Hoang, Joseph H.
Cheung, Ramsey
Eguchi, Yuichiro
Ueno, Yoshiyuki
Furusyo, Norihiro
Yu, Ming-Lung [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Tanaka, Yasuhito
Nguyen, Mindie H.
机构：
[1] Kaohsiung Med Univ Hosp, Dept Internal Med, Hepatobiliary Div, Kaohsiung, Taiwan
[2] Kaohsiung Med Univ, Coll Med, Hepatitis Res Ctr, Kaohsiung, Taiwan
[3] Kaohsiung Med Univ, Cohort Res Ctr, Kaohsiung, Taiwan
[4] Kaohsiung Chang Gung Mem Hosp, Dept Internal Med, Div Hepatogastroenterol, Kaohsiung, Taiwan
[5] Natl Sun Yat Sen Univ, Sch Med, Kaohsiung, Taiwan
[6] Natl Sun Yat Sen Univ, Coll Med, Doctoral Program Clin & Expt Med, Kaohsiung, Taiwan
[7] Natl Sun Yat Sen Univ, Ctr Excellence Metab Associated Fatty Liver Dis, Kaohsiung, Taiwan
来源：
ALIMENTARY PHARMACOLOGY & THERAPEUTICS | 2024年 / 59卷 / 05期
关键词：
D O I：
10.1111/apt.17885
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：725 / 725
页数：1
相关论文
共 50 条
  • [21] Plasma and breast milk pharmacokinetics of tenofovir alafenamide in mothers with chronic hepatitis B infection (vol 56, pg 510, 2022)
    Kayes, T.
    Crane, H.
    Symonds, A.
    Dumond, J.
    Cottrell, M.
    Di Girolamo, J.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2023,
  • [22] Tenofovir alafenamide for pregnant chinese women with active chronic hepatitis B: a multicenter, prospective, real-world study
    Zeng, Qing-Lei
    Zhang, Hongxu
    Zhang, Ji-Yuan
    Huang, Shuo
    Li, Wei-Zhe
    Li, Guangming
    Feng, Ying-Hua
    Zhang, Guofan
    Xu, Jiang-Hai
    Lin, Wan-Bao
    Xu, Guang-Hua
    Zhang, Guoqiang
    Zeng, Yan-Li
    Yu, Zu-Jiang
    Wang, Fu-Sheng
    JOURNAL OF HEPATOLOGY, 2022, 77 : S827 - S827
  • [23] Improved bone and renal safety in younger tenofovir disoproxil fumarate experienced chronic hepatitis B patients after switching to tenofovir alafenamide or entecavir
    Wang, Fa-Da
    Zhou, Jing
    Li, Lan-Qing
    Li, Yu-Jing
    Wang, Meng -Lan
    Tao, Ya-Chao
    Zhang, Dong-Mei
    Wang, Yong-Hong
    Chen, En-Qiang
    ANNALS OF HEPATOLOGY, 2023, 28 (05)
  • [24] Sequential therapy from entecavir to tenofovir alafenamide versus continuous entecavir monotherapy for patients with chronic hepatitis B (vol 5, pg 34, 2021)
    Itokawa, Norio
    Atsukawa, Masanori
    Tsubota, Akihito
    Takaguchi, Koichi
    Nakamuta, Makoto
    Hiraoka, Atsushi
    Kato, Keizo
    Abe, Hiroshi
    Mikami, Shigeru
    Shimada, Noritomo
    Chuma, Makoto
    Nozaki, Akito
    Uojima, Haruki
    Ogawa, Chikara
    Asano, Toru
    Tani, Joji
    Morishita, Asahiro
    Senoh, Tomonori
    Yamashita, Naoki
    Oikawa, Tsunekazu
    Matsumoto, Yoshihiro
    Koeda, Mai
    Yoshida, Yuji
    Tanabe, Tomohide
    Okubo, Tomomi
    Arai, Taeang
    Hayama, Korenobu
    Iwashita, Ai-Nakagawa
    Kondo, Chisa
    Tada, Toshifumi
    Toyoda, Hidenori
    Kumada, Takashi
    Iwakiri, Katsuhiko
    JGH OPEN, 2021, 5 (03): : 410 - 410
  • [25] Real-world experience of switching from tenofovir disoproxil fumarate to tenofovir alafenamide in patients with chronic hepatitis B: a retrospective study
    Su, Pei-Yuan
    Su, Wei-Wen
    Hsu, Yu-Chun
    Huang, Siou-Ping
    Yen, Hsu-Heng
    PEERJ, 2021, 9
  • [26] IMPROVEMENT IN VIROLOGIC, BIOCHEMICAL AND RENAL OUTCOMES IN CHRONIC HEPATITIS B (CHB) PATIENTS SWITCHED TO TENOFOVIR ALAFENAMIDE (TAF) IN ROUTINE CLINICAL PRACTICE
    Yeh, Ming-Lun
    Trinh, Sam
    Huang, Chung-Feng
    Hsieh, Ming-Yen
    Huang, Ching-I
    Liang, Po-Cheng
    Huang, Jee-Fu
    Dai, Chia-Yen
    Chuang, Wan Long
    Nguyen, Mindie H.
    Yu, Ming-Lung
    HEPATOLOGY, 2019, 70 : 295A - 296A
  • [27] HERACLIS-TAF: a multicentre prospective cohort study on 2-year safety and efficacy of tenofovir alafenamide in patients with chronic hepatitis B with renal and/or bone disorders or risks
    Papatheodoridis, George, V
    Mimidis, Kostas
    Manolakopoulos, Spilios
    Gatselis, Nikolaos
    Goulis, John
    Kapatais, Andreas
    Manesis, Emanuel
    Vasiliadis, Themistoklis
    Triantos, Christos
    Samonakis, Dimitrios
    Sevastianos, Vasilios
    Karatapanis, Stelios
    Elefsiniotis, Ioannis
    Deutsch, Melanie
    Mylopoulou, Theodora
    Papatheodoridi, Margarita
    Kranidioti, Hariklia
    Agorastou, Polyxeni
    Karaoulani, Theofani
    Kyriazidou, Anastasia
    Zisimopoulos, Konstantinos
    Dalekos, George N.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2022, 56 (04) : 702 - 712
  • [28] Effects of tenofovir disoproxil fumarate versus tenofovir alafenamide on risk of osteoporotic fracture in patients with chronic hepatitis B : a nationwide claims study
    Kim, Eunju
    Lee, Hyun Woong
    Lee, Kwan Sik
    JOURNAL OF HEPATOLOGY, 2023, 78 : S1132 - S1133
  • [29] Editorial: changes in renal function and bone mineral density after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in chronic hepatitis B patients-author's reply
    Papatheodoridis, George V.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2022, 56 (05) : 918 - 919
  • [30] Changes in blood lipids in patients with chronic hepatitis B after 48 weeks of tenofovir alafenamide treatment: A prospective real-world clinical study
    Zhang, Yeqiong
    Li, Zhipeng
    Luo, Qiumin
    Xu, Wenxiong
    Wang, Lu
    Zhu, Shu
    Peng, Liang
    Xie, Chan
    ANTIVIRAL THERAPY, 2022, 27 (01)
12345